SLC15A3

Across TCGA pan-cancer cohorts, SLC15A3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SLC15A3 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SLC15A3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC15A3 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LUAD, GBM, and PDAC are the cancer types where SLC15A3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.418	0.983	.005	12	view →
GBM	OS	Tertile	All	0.988	0.734	.004	10	view →
PDAC	DFS	Median	III,IV	0.223	0.919	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SLC15A3–LUAD (DFS)

Open the LUAD breakdown →